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A number of beta-thalassemia patients, independently from the type of beta-thalassemia
(β0 or β+) and blood transfusion requirements, may develop, after puberty, dermal,
cardiovascular, and ocular complications associated with an ectopic mineralization
phenotype similar to that observed in another rare genetic disorder, namely,
Pseudoxanthoma elasticum (PXE). To date, the causes of these alterations in
beta-thalassemia patients are not known, but it has been suggested that they could be
the consequence of oxidative stress-driven epigenetic regulatory mechanisms producing
an ABCC6 down-regulation. Since, in the last years, several genes have been associated
to the ectopic mineralization phenotype, this study, for the first time, applied, on
beta-thalassemia patients with ectopic mineralization phenotype, a multigene testing
strategy. Selection of genes to be analyzed was done on the basis of (i) their genetic
involvement in calcification diseases or (ii) their role in calcium-phosphate equilibrium.
Although, due to the rarity of these conditions, a limited number of patients was
analyzed, the detection of pathogenic variants represents the proof of concept that
PXE and beta-thalassemia traits co-occur on a genetic basis and that, in addition to
causative mutations, functional polymorphisms may further influence connective tissue
manifestations. The use of a multigene-based next-generation sequencing represents
a useful time- and cost-effective approach, allowing to identify sequence variants
that might improve prognostic assessment and better management of these patients,
especially in the current era of precision medicine aiming to identify individual optimal
care based on a unique personal profile.
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INTRODUCTION
Beta-thalassemia (β-thal) (OMIM 613985) is a genetic disorder caused by mutations in the
β-hemoglobin (HBB) gene that determines either a reduced (β+) or absent (β0) synthesis of the
β-globin chains. In addition to hematological findings, according to the literature, up to 10% of
β-thal patients (1) exhibit clinical manifestation similar to those observed in Pseudoxanthoma
elasticum (PXE) (OMIM 264800), a rare genetic disease in which ABCC6 gene mutations cause
the mineralization of elastic fibers responsible for skin, ocular, and cardiovascular complications
that generally start after puberty and continuously progress with age (2).
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FIGURE 1 | PXE clinical features in beta-thalassemia patients. (A) Skin
papules (arrows) typically located on the neck; (B) fluoroangiography showing
angioid streaks (arrows) as irregular lines spreading from the optic nerve to the
retinal periphery.
A first study failed to detect ABCC6 gene mutations in
10 β-thal patients with soft connective tissue complications
(3) and in the light of these data, the involvement, in
these patients, of ABCC6 gene mutations in the pathogenesis
of PXE-like alterations was ruled out. Therefore, PXE-like
manifestations in β-thal patients have been hypothesized to be
the consequence of oxidative stress-driven epigenetic regulatory
mechanisms causing ABCC6 down-regulation (4). However, in
the recent years, the expanding knowledge on the mechanisms
controlling the mineralization process has revealed that, in
addition to ABCC6, several other genes can be responsible for
ectopic mineralization phenotypes (2), but, to our knowledge,
a multigene approach has not been applied to patients in
which beta-thalassemia is associated with PXE-like connective
tissue manifestation.
The aim of this study was to define a multigene next-
generation sequencing to identify pathogenic variants in
three unrelated β-thal patients exhibiting soft connective
tissue manifestations.
MATERIALS AND METHODS
Patients
In the present study, three unrelated beta-thalassemia female
patients with skin papules and/or skin laxity typical of PXE
(Figure 1A) and by ocular angioid streaks (Figure 1B) have
been investigated.
The diagnosis of beta-thalassemia was based on the usual
hematological criteria (peripheral blood evaluation and
hemoglobin electrophoresis) and on the presence of mutations
in HBB gene. Two patients (#1 and #3) were diagnosed with
β-thalassemia Major and were carrier of a pathogenic variant in
intron 1 (IVS1-110G>A in the homozygous state) and a stop
codonmutation in exon 2 (c.C118T, p.Gln40∗ in the homozygous
state), respectively. Both patients required blood transfusion and
chelation therapy. The third patient (#2) was diagnosed with
β-thalassemia and was carried of a pathogenic variant in intron
1 (IVS1-110G>A in the heterozygous condition). This patient
never required blood transfusion.
Clinical laboratory tests (i.e., Ca, P, intact PTH, and ALPL)
were within normal ranges.
FIGURE 2 | (A) Gene–protein interaction network. Gene relationships were
obtained by STRING 11 (Search Tool for the Retrieval of Interacting
Genes/Proteins) software. STRING parameters included: Active Prediction
Methods: Textmining (yellow), Experiments (violet), Databases (light blue), and
Co-expression (black); max number of interactors: none. ABCC6 = Multidrug
resistance-associated protein 6; ALPL = Alkaline phosphatase,
tissue-non-specific isozyme; AHSG, Alpha-2-HS-glycoprotein; ANKH,
Progressive ankylosis protein homolog; ENPP1, Ectonucleotide
pyrophosphatase/phosphodiesterase family member 1; FGF23, Fibroblast
growth factor 23; GALNT3, Polypeptide N-acetylgalactosaminyltransferase 3;
GGCX, Vitamin K-dependent gamma-carboxylase; KL, Klotho; MGP = Matrix
Gla protein; NT5E, 5’-nucleotidase; PLG, Plasminogen; PPA1, Inorganic
pyrophosphatase; PPA2, Inorganic pyrophosphatase 2; SAMD9, Sterile alpha
motif domain-containing protein 9; SLC20A1, Sodium-dependent phosphate
transporter 1; SLC20A2, Sodium-dependent phosphate transporter 2; SPP1,
Osteopontin; VKORC1, Vitamin K epoxide reductase complex subunit 1. (B)
Schematic representation of functional roles of calcification-related genes.
Localization, substrate specificity, and/or transported molecules are reported
for the investigated genes.
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The study was done, with informed consent, in accordance
with the basic principles of the Declaration of Helsinki and
approval by the local Ethical Committee (Comitato Etico
Provinciale di Modena) (n. 358/17).
Targeted Exome Sequencing
DNA was extracted from whole blood using standard
methods and quantified and quality tested using the
Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) and
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). Samples were subjected to target exome
sequencing. A DNA custom panel was designed with
AmpliSeq Custom DNA Panel for Illumina and sequenced on
NextSeq500 (Illumina).
Raw reads were quality trimmed at both ends with ERNE-filter
v1.4.3 (5) using default parameters and minimum read length
of 40 bp.
Reads were aligned to the human reference genome
(GRCh37/hg19 assembly) and only reads, mapping to unique
positions, were retained. Variant discovery and functional
annotation were performed by the software tool ANNOVAR (6).
Analyses were performed focusing on a panel of 19 genes,
12 of them are responsible for calcification-related diseases and
7 of them play a role in calcium-phosphate equilibrium (7–13)
(Figures 2A,B and Table S1).
Filtering of Genetic Variants
Analyses were carried out primarily looking at coding
and splice site regions excluding reference sequences and
variants that do not change the translated amino acid
sequence (i.e., synonymous). Thereafter, the frequency of
each sequence variant was assessed querying databases as
dbSNP138 build, 1,000 Genomes Project (1000g2012apr_all),
and ESP6500si_all in order to discriminate common
variants, with a minor allele frequency ≥1%, and rare
sequence variants.
In Silico Analysis for Functional Prediction of Variants
For rare sequence variants not yet reported in the literature
as pathogenic, the pathogenicity score was predicted by
Sorting Intolerant From Tolerant (SIFT) (14), Polymorphism
Phenotyping (Polyphen2) (15), and Panther (16), whereas the
Genomic Evolutionary Rate Profiling (GERP++) (17) method
and the Phylogenetic P-values (PhyloP) (18) were used to
estimate the level of single-nucleotide variation conservation. To
predict protein stability I-Mutant and MUpro were used (19).
Sanger Sequencing
All pathogenic variants were confirmed by conventional
Sanger sequencing. Primer sequences were designed by NCBI
Primer-BLAST software, and purified PCR products were
directly sequenced using an Applied Biosystems 3100 DNA
sequencer (20).
RESULTS AND DISCUSSION
Unexpectedly, rare sequence variants were detected in ABCC6
and ENPP1 genes (Table 1 and Figure S1).
ABCC6 is well-known as a PXE causing gene, encoding for
a transmembrane protein (MRP6) probably involved in the
extrusion of ATP (Figure 2B) (21).
ENPP1 encodes for an ectonucleotide-
pyrophosphatase/phosphodiesterase-1 that utilizes adenosine
triphosphate to release pyrophosphate (PPi) (2, 22), a potent
inhibitor of ectopic calcification (Figure 2B).
Note that ABCC6 and ENPP1 have been both recently
recognized as PXE causing genes (22).
Patient #1 was homozygous for ABCC6Arg391Gly (22), patient
#2 was compound heterozygous for ABCC6Phe1352Ser and
ABCC6Arg1114Cys (22), and patient #3 was heterozygous for
ABCC6Arg391Gly and for ENPP1Arg886Thr (Table 1).
Of these variants, ABCC6Phe1352Ser and ENPP1Arg886Thr were
never found in the literature, but, for both missense variants, the
prediction scores implied a probably damaging effect (Table S2).
Present data underline the importance of ABCC6 and also
provide evidence that, in one patient, anABCC6 pathogenic allele
is associated with a new rare sequence variant in the ENPP1 gene
(c.2657G > C, p.Arg886Thr), where a substitution of the highly
conserved arginine in position 886 with a threonine can affect the
structural stability and the functional properties of the protein
due to different polarity, charges, and size of these two amino
acids. In the light of these data, a digenic inheritance of PXE
manifestation could be suggested, as already shown for ABCC6
and GGCX (23).
Sequence variants were never detected in the following genes:
AHSG, ANKH, GALNT3, KL, PLG, PPA1, SLC20A1, SLC20A2,
and VKORC1. However, the absence of rare sequence variants
and/or single-nucleotide polymorphisms (SNPs) in these genes
does not exclude a priori their possible role in the development of
ectopic mineralization phenotypes, and therefore, in perspective,
studies on a larger cohort of patients would better elucidate
this aspect.
SNPs were detected in other genes (Table 2 and Table S3).
Interestingly, two of these polymorphisms have been reported
in the literature to modulate the ectopic mineralization
phenotype: rs1044498 in ENPP1 (24) and rs7955866 in
FGF23 (25).
ENPP1Lys173Gln is a functional polymorphism found in all
three patients in the homozygous (#1) or heterozygous state (#2
and #3). This polymorphism (c.517A>C; p.Lys173Gln) has been
demonstrated to reduce enzyme activity, thus causing diminished
calcification inhibitory properties of inorganic pyrophosphate
(PPi) (24) and consequently predisposing to cardiovascular
complications as coronary calcification and earlier onset of
peripheral arterial disease.
Moreover, it could be suggested that rare sequence variants
and/or functional polymorphisms in ENPP1 can act in synergy
with epigenetic regulatory mechanisms. The oxidative stress
condition, in fact, can down-regulate, by epigenetic mechanisms,
the activity of ENPP1 (26) and this finding is of special interest in
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TABLE 1 | Clinical/demographic data of patients (#1, #2, and #3) and rare sequence variants found in HBB, ABCC6, and ENPP1 genes.
ID
(Age/Gender)
Rare sequence variants
HBB ABCC6 ENPP1
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
#1
(28/F)
IVS1-110G>A IVS1-110G>A c.1171A>G
p.Arg391Gly
c.1171A>G
p.Arg391Gly
– –
#2
(31/F)
IVS 1-110G>A – c.4055T>C
p.Phe1352Ser
c.3340C>T
p.Arg1114Cys
– –
#3
(27/F)
c.118C>T,
p.Gln40*
c.118C>T,
p.Gln40*
c.1171A>G
p.Arg391Gly
– c.2657G>C
p.Arg886Thr
–
Characteristic of rare sequence variants reported in this study
Gene symbol Variant Genomic coordinates
(GRCh37)
Exon/Intron dbSNP ID Frequency
1,000G
HBB IVS1-110G>A chr11:
5248050
Intron1 rs35004220 NA
c.118C>T chr11:
5248004
Exon2 rs11549407 0.000
ABCC6 c.1171A>G chr16:
16295863
Exon9 rs72653762 0.003
c.3340C>T chr16:
16257016
Exon24 rs63749794 0.000
c.4055T>C chr16:
16248638
Exon29 NA NA
ENPP1 c.2657G>C chr6:
132211530
Exon25 rs8192683 0.003
New rare sequence variants are highlighted in bold.
NA, not available.
TABLE 2 | Single-nucleotide polymorphisms (SNPs) found in at least one patient.
Gene Common sequence variants
SNP ID Nucleotide
change
Amino acid
change
Genotypes
#1 #2 #3
ABCC6 rs2238472 c.3803G>A Arg1268Gln AA GG GA
ALPL rs3200254 c.787T>C Tyr263His TT TT TC
ENPP1 rs1044498 c.517A>C Lys173Gln CC AC AC
FGF23 rs7955866 c.716C>T Thr239Met CC CC CT
GGCX rs699664 c.974G>A Arg325Gln GG GA GA
MGP rs4236 c.304A>G Thr102Ala AG AA AG
NT5E rs2229523 c.1126A>G Thr376Ala GG GG GG
PPA2 rs13787 c.846G>C Lys282Asn CC GG GG
SAMD9 rs10239435
rs6969691
c.1346A>G
c.428T>C
Asn449Ser
Ile143Thr
AA
TT
AA
TT
AG
TC
SPP1 rs11728697 c.71C>T Ala24Val CC TT TT
β-thal patients who are known to be characterized by an altered
redox balance (27).
As far as FGF23Thr239Met , this SNP, found in patient #3
in the heterozygous condition, has been reported to influence
FGF23 biological function, providing an increased stability of the
protein, thus influencing phosphate homeostasis and favoring
kidney stone formation (25).
Interestingly, the ABCC6Arg1268Gln sequence variant was
detected in two patients, in the homozygous (#1) and in the
heterozygous state (#3). Although considered in early studies
to be pathogenic, given its frequency (19%), it has been later
considered as a functional polymorphism contributing to the
development and/or severity of angioid streaks (28, 29) and
therefore cannot be disregarded in a prognostic assessment.
As far as rs699664 in GGCX, rs4236 in MGP, and rs2229523
in NT5E genes, data in the literature (30–32) indicate that SNPs
observed in our patients determine either an enzyme activity
similar to wildtype (GGCXArg325Gln and NT5EThr376Ala) or absent
association with increased risk of calcification (MGPThr102Ala)
and therefore their functional contribution to the ectopic
mineralization phenotype can be likely irrelevant.
To our knowledge, other SNPs found in ALPL (rs3200254),
PPA2 (rs13787), SAMD9 (rs10239435 and rs6969691), and SSP1
(rs11728697) genes have not been investigated for their possible
functional role, and therefore, at present, pathogenic hypotheses
cannot be put forward.
Evidence is provided that there are patients in which,
independently from the type of beta-thalassemia (β0 or β+) and
blood transfusion requirements, PXE clinical manifestations can
occur on a genetic basis.
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These data are partially in contrast to previous observations
suggesting the absence of ABCC6 pathogenic variants in β-thal
patients (3). This discrepancy could be due to (i) the continuously
increasing number of recognized pathogenic variants (>350)
since the discovery of ABCC6 as the causative PXE gene and (ii)
the demonstrated pathogenic role of other genes in addition to
ABCC6 (2, 22).
CONCLUSION
Considering the current longer life expectancy of β-thal patients,
the development of complications that appear and progress with
age should deserve higher consideration in both clinical and
genetic evaluations. In the light of present data, searching for
sequence variants in calcification-related genes also at the pre-
symptomatic stage is recommended for a better management of
β-thal patients and of their possible complications. Moreover,
although this condition may affect a limited number of patients,
genetic tests, given their increasing widespread distribution, can
easily provide high-throughput and informative data to make a
more accurate diagnostic and prognostic assessment, especially
in the current era of precision medicine, distinguishing a given
patient from other patients with similar clinical phenotype.
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